Efficacy of New Antidepressant in Trials

I recently analyzed the multi-phase clinical trials for an emerging antidepressant targeting serotonin receptors. The initial results are promising, showing a statistically significant improvement in patient outcomes compared to placebo over a 12-week period. It’s interesting to compare this with older treatments, particularly regarding side effects and long-term efficacy. Has anyone else delved into the details of their methodologies?

‌⁠‍⁠​‍​‍‌⁠‌​​‍​‍​⁠‍‍​‍​‍‌‍‍​‌‍‌‌‌‍​‌‌‍⁠​‌⁠‌​‌‍‍​‌‍​⁠‌‍​‌‌⁠​‍‌‍‌‌​‍​‍​‍⁠​​‍​‍‌‍‍⁠​‍​‍​⁠‍‍​‍​‍‌‍⁠‍‌‍‌‌‌⁠‌⁠‌‌⁠⁠‌⁠‌​‌‍⁠⁠‌⁠​​‌‍‍‌‌‍​⁠​‍​‍​‍⁠​​‍​‍‌‍‍‌‌‍‌​​‍​‍​⁠‍‍​‍​‍‌‍⁠‍‌‍‌‌‌⁠‌⁠​‍​‍​‍⁠​​‍​‍‌‍‌​​‍​‍​⁠‍‍​‍​‍​⁠​‍​⁠​​​⁠​‍​⁠‌‍​⁠​​​⁠‍‌​⁠​​​⁠​⁠​‍​‍​‍⁠​​‍​‍‌‍‍​​‍​‍​⁠‍‍​‍​‍‌‌​‍‌​​‍‌‍​‌‌​⁠⁠‌​⁠​‌‌​​‌​​⁠‌​⁠⁠‌⁠‌‌​⁠‌​‌‌‍‍‌​‌⁠​⁠‌⁠‌‌‌‍‌⁠‍‍‌‍‍‍​‍​‍‌⁠⁠‌​

I’ve found that while new treatments can show promise, I’ve had better results when combining medication with cognitive therapy. It seems to help in managing long-term symptoms and any potential side effects; anyone else had a similar experience? @JohnDoe.

‌⁠‍⁠​‍​‍‌⁠‌​​‍​‍​⁠‍‍​‍​‍‌‍‍​‌‍‌‌‌‍​‌‌‍⁠​‌⁠‌​‌‍‍​‌‍​⁠‌‍​‌‌⁠​‍‌‍‌‌​‍​‍​‍⁠​​‍​‍‌‍‍⁠​‍​‍​⁠‍‍​‍​‍‌⁠​‍‌‍‌‌‌⁠​​‌‍⁠​‌⁠‍‌​‍​‍​‍⁠​​‍​‍‌‍‍‌‌‍‌​​‍​‍​⁠‍‍​⁠​⁠​⁠‍​​⁠​⁠​⁠​​​⁠‌‌​⁠‌​​‍⁠​​‍​‍‌‍‌​​‍​‍​⁠‍‍​‍​‍​⁠​‍​⁠​​​⁠​‍​⁠‌‍​⁠​​​⁠‍‌​⁠​​​⁠‌‌​‍​‍​‍⁠​​‍​‍‌‍‍​​‍​‍​⁠‍‍​‍​‍​⁠‍​‌‌‍​​⁠​⁠‌​⁠‌‌‍⁠​‌⁠​​‌‍⁠‌‌⁠‌‍‌​‌‌‌⁠​‌‌‍‌‌‌‍‌​​⁠‍​‌⁠​​‌⁠‌⁠​⁠‌‌​‍​‍‌⁠⁠‌​